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Cervical cancer is one of the most common and lethal cancers in West Africa. Even though
vaccines that protect against the most common Human papillomavirus (HPV) strains, 16
and 18, are currently in use in developed countries, the implementation of these vaccines in
developing countries has been painfully slow, considering the pre-eminence of HPV-associ-
ated cervical cancer among women in those countries.
Aim
We performed serological and PCR-based assessment of blood and tissue specimens
obtained from women undergoing cervical cancer-related surgery at a major urban hospital
in Bamako. Since several therapeutic HPV vaccines are currently in clinical trials, we also
assessed willingness to participate in HPV cancer vaccine trials.
Methods
Blood and biopsy samples of 240 women were evaluated for HPV types 16 and 18 by serol-
ogy and PCR. Knowledge regarding the HPV vaccine and autonomy to decide to vaccinate
their own child was assessed with a standardized questionnaire.
Results
HPV 16 and 18 were identified in 137/166 (82.5%) cervical cancer biopsy samples by PCR.
Co-infection with both HPV 16 and 18 was significantly more frequent in women over 50
years of age than in younger women (63.0% vs. 37.0%). 44% of study participants said they
would be willing to vaccinate their child with HPV vaccine. Only 39% of women participating
in this study reported that they would be able to make an autonomous decision to receive
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Conclusion
This study provides strong support for the introduction of currently available HPV vaccines
in Mali, and also provides key information about conditions for obtaining informed consent
for HPV vaccine trials and HPV vaccination in Mali.
Introduction
Nearly 85% of the half a million cervical cancer (CC) cases diagnosed each year occur in devel-
oping world countries. There are 27,300 new cases of CC identified in West Africa every year,
and 16,500 deaths per year are attributed to CC [1]; CC is the second most common and lethal
cancer among women in the region. Mali, a landlocked sub-Saharan West African country has
an estimated population of 4.04 million women aged 15 and over, and the highest regional rate
of CC (44.2 cases of CC per 100,000 women [2]. Cervical cancer is the leading cause of all can-
cer-related mortalities among women aged 15 to 44 years in Mali. Sixty-eight percent of
women diagnosed with CC in Mali do not survive, an equivalent of 1,261 deaths per year [3].
The high mortality rate is likely due to the low accessibility of CC screening: according to
household surveys performed by WHO, only 4% of women have ever been screened for CC
[3]. The mortality rate from cervical cancer may actually be higher than reported here, as
many residents of Mali are unable to afford medical care (78% of the population earned less
than $3.10 per day in 2009 [4]) and thus cancer cases are likely to be under-reported.
The main risk factor of CC is infection with high-risk types of human papillomavirus (HPV)
[5]. As defined by the World Health Organization (WHO), there are 12 high-risk cancer-caus-
ing HPV types [6]. Among them, HPV types 16 and 18 are found in 60% to 70% of invasive cer-
vical cancer (ICC) cases in Africa [7–10]. The prevalence of high-risk types is lower among
women who have not been diagnosed with cervical cancer. The prevalence of high-risk types
has been estimated to be 12% among Malian women aged 15–65 [11,12] and was reported to be
23% in urban women living in Bamako, Mali in 2013 [13]. Prevention of HPV infection by pro-
phylactic vaccines may address this major public health concern. Therapeutic vaccines for the
treatment of cervical cancer are in clinical trials [14,15] these vaccines primarily focus on high-
risk types HPV 16 and 18. Thus it is important to determine the usefulness of available HPV
vaccines by evaluating the prevalence of high-risk HPV types in cervical cancer patients.
The most recent HPV typing data trace back to 1995 and 2002 which showed that high-risk
HPV types 16 and 18 could be identified in 54% to 62% of CC cases in Mali [16,17]. To address
the lack of recent data on the prevalence of high-risk HPV types among women being treated
for cervical cancer in Mali, we evaluated the prevalence of HPV subtypes 16 and 18 among
women who had histologically confirmed diagnoses of CC at Hoˆpital Gabriel Toure´ in
Bamako, Mali by PCR. We also assessed the knowledge, attitudes and practices regarding vac-
cination and determined willingness to participate in a clinical trial of an HPV vaccine.
Methods
Recruitment of participants
Hoˆpital Gabriel Toure´ has an annual admissions rate of about 16,500 patients and serves two
million patients in the direct community surrounding the hospital (Bamako proper) and 12
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million in total across the wider region. It is the primary referral hospital for cervical cancer in
Mali and 95% of cervical cancer patients diagnosed in Bamako are referred to this hospital.
During the study period more than 3,344 patients were seen in the department of gynecol-
ogy, of which 10% were diagnosed with cervical cancer (roughly 334). This study was per-
formed over 20 months during that period and captured nearly 88% of the patients who had
cervical cancer confirmed by biopsy during that period.
From June 2011 to January 2013, all patients with histologically confirmed CC were
approached by clinicians at the Gabriel Toure´ Hospital and asked whether they would be will-
ing to participate in a study of HPV infection and in a survey. 240 women agreed to partici-
pate; informed consent was obtained for their participation. No compensation was offered in
exchange for participation in the study. 240 women consented to the use of their cervical
biopsy specimen and provided blood for serology; 235 women answered the survey questions
(five declined to participate in the survey portion of the study). Cervical biopsy specimens and
serum samples were processed at the Laboratory of Applied Molecular Biology at the Univer-
sity of Bamako.
Collection of general and medical information and knowledge and
attitude toward vaccination
A standardized questionnaire was read to the participants in order to collect general and medi-
cal information and willingness to participate (WTP) in an HPV vaccination program and vac-
cination decision-making capacity. The questionnaire used in this study was adapted from a
pilot study published by our group in 2013 [18]. The structured interviews were conducted in
Bambara, the primary language in Mali, by trained medical staff. An English translation of the
survey document is provided in the supporting information file (see S1 File).
Sample collection
Whole blood samples (4 mL) were collected and centrifuged at 4000 rpm for 20 minutes;
serum samples were transferred in cryovials, stored at -80˚C and sent to an immunology labo-
ratory (PPD Vaccines and Biologics Lab, Wayne, PA) for serological marker detection of HPV
subtypes 16 and 18 (see below). Cervical biopsies were collected in 400 μL of 10X Dulbecco’s
Phosphate-Buffered Saline (PBS, Life Technologies, Grand Island, NY) and stored at -80˚C for
further examination by polymerase chain reaction (PCR) assay for detection of HPV 16 and 18
DNA.
DNA extraction and HPV detection by PCR
Total DNA was extracted from biopsies using the QIAamp DNA Blood Mini Kit (Qiagen,
Valencia, CA) following the manufacturer’s instructions: 15–25 mg tissue sections were
applied to a clean single-edge blade using strict aseptic technique to prevent contamination or
cross-contamination of samples. The samples were digested overnight at 55˚C in the lysis
Buffer AL containing protease K (Qiagen, Valencia, CA), followed by precipitation of DNA
with absolute ethanol in a spin column. The DNA was eluted with Buffer AE (Qiagen, Valen-
cia, CA). DNA purity and concentration were quantified using a BioPhotometer (Eppendorf,
Hauppauge, NY). Two sets of primers specific to the E6 oncogene were used to detect HPV
types 16 and 18 DNA (p16F/p16R and p18F/p18R, respectively, Table 1) [19–21]. The expected
size for both PCR products was 140 bp. DNA integrity was determined by amplification of the
human β-globin gene prior to HPV PCR assay, as described in the literature [19,22] using Glo-
bin-1 and -2 primers (Table 1). The expected size for the PCR product was 268 bp.
HPV prevalence in Malian cervical cancer patients
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The PCR assays were performed as described by others [21,22] with minor modifications.
All reagents were from Life Technologies, Carlsbad, CA, unless otherwise specified. Briefly,
test sample DNA (10 to 200 ng) was added to a mixture containing dNTP (0.2 mM each), Taq
polymerase (0.04 U), reaction buffer (1X), MgCl2 (1.5 mM), reverse and forward primers for
HPV 16 or HPV 18 (0.5 μM each; Eurofins MWG, Les Ulis, France); PCR-quality water was
used to reach a final volume of 25 μL. To avoid false positive and/or negative results, a negative
control (no template DNA) and an HPV-positive DNA sample were included in each assay.
PCR amplification was performed using a DNA Thermocycler (MJ Research, Waltham, MA,
USA), as follows: 5 min at 94˚C, 40 cycles (94˚C, 1 min; 65˚C, 1 min; 72˚C, 2 min) and a final
7 min extension period at 72˚C.
As a control of the PCR product size, 12 μl of PCR product were loaded on a 2% 0.5X TBE
buffer agarose gel, stained with 0.3 mg/mL ethidium bromide, and photographed by UV trans-
illumination with a KODAK EDAS 290. The molecular weight of the PCR products was deter-
mined by comparison to DNA molecular weight marker XIV (Roche Diagnostics, Mannheim,
Germany).
Detection of HPV antibodies by cLIA assays
The presence of antibodies to HPV types 16 and 18 was detected by a VLP-based competitive
Luminex immunoassay (cLIA) using a multiplexed Laboratory Multi-Analyte Profiling (Lab-
MAP3) assay system (Luminex Corporation, Austin, TX) as previously described [23,24].
Briefly, HPV VLPs 16 and 18 (Merck & Co., Whitehouse Station, NJ, USA) were covalently
coupled to fluorescent microsphere beads (Luminex Corporation, Austin, TX) according to
the manufacturer’s instructions and stored at a concentration of 1.25x107 microspheres/mL in
the dark at 4˚C. A total of 5,000 of each VLP16- and VLP18-microspheres were combined
with 50 μl of 1:4 diluted blood samples in a dark 96-well plate. To each well, 25 μl of HPV type-
specific mAbs conjugated to PE (Merck & Co., Whitehouse Station, NJ, USA) were added, fol-
lowed by an overnight incubation at room temperature. Samples were transferred to a filter
plate (Millipore, Bedford, MA) and washed in PBS; the VLP-microspheres were re-suspended
in 200 μl of PBS containing 1% BSA for analysis on a BioPlex Suspension Array System
(BioRad, Hercules, CA).
The reference standard used for analysis was a serial two-fold dilution of a pool of serum
samples from African green monkeys hyperimmunized with monovalent HPV L1 VLP types
16 and 18. Dilution-corrected serum values (in mMU/mL) were computed based on a four-
parameter logistics fit of the standard curve on each assay plate. Samples that exceeded the lim-
its of quantitation for the standard curve were retested at higher dilutions. Samples were con-
sidered Ab seropositive for the respective HPV subtype if the cLIA signal was11 mMU for
HPV 16 and10 mMU for HPV 18. All standards, controls, and samples were tested in
duplicate.
Table 1. Primer sequences.





Globin-1 GAA GAG CCA AGG ACA GGT AC
Globin-2 CAACTTCATCCACGTTACACC
doi:10.1371/journal.pone.0172661.t001
HPV prevalence in Malian cervical cancer patients
PLOS ONE | DOI:10.1371/journal.pone.0172661 February 23, 2017 4 / 13
Statistical analysis
GraphPad (http://www.graphpad.com) was used to calculate 95% confidence intervals. The
Fisher test was applied to determine significant differences between groups. p<0.01 was con-
sidered significant.
Ethics statement
The study protocols for obtaining informed consent, tissue samples, blood tests, and surveys
were reviewed and approved by the Committee of Ethics of the Faculty of Medicine, Pharmacy
and Odonto-stomatology (FMPOS) in Bamako, Mali. The informed consent document was
translated from French to Bambara. The consent form was read aloud to individuals who were
illiterate. All participants provided a signature or fingerprint indicating their informed con-
sent. All participants were over 18 years old.
Results
Characteristics of women diagnosed with CC
Between June 2011 and January 2013, all of the patients undergoing biopsy for cervical cancer
at Hoˆpital Toure´, the primary referral hospital for cervical cancer in the region of Bamako,
were approached to participate in this study. 88% (240) of the more than 270 women who had
biopsies during that period agreed to have their serum obtained and their biopsy specimen
evaluated for HPV testing. Of these 240 women, 235 agreed to participate in the structured
interview.
Characteristics of the study participants are summarized in Table 2. The mean age of the
participants was 50.0 years (SD: 13.2); with 133 (56.6%) of the participants aged 20–50 years
and 102 (43.4%) aged over 51 years. Of the 231 (98.3%) participants who were married
(including divorced and widows), 51 (22.1%) reported having been in polygamous marriages.
The mean age of first marriage and when the first child was born was 17.0 years (SD: 2.7 and
2.3, respectively) and the mean age for sexual debut was 16.0 years (SD: 2.1). Among the 229
women with children, the average number of children was 6 (SD: 2.9). Only 40 patients
(17.0%) had attended either primary or secondary school and 27 (11.5%) had been employed
outside their home.
The mean age of CC diagnosis was 49.0 years (SD: 13.6): 142 participants (60.4%) were
diagnosed between the ages of 20–50 years, and 92 (39.1%) were diagnosed between 50–90
years. 134 participants (57.0%) reported having previous sexually transmitted infections
(STIs).
Prevalence of HPV 16 and HPV 18 infection
Cervical biopsy samples (N = 240) were tested by PCR using human β-globin pair primers as a
control for sample integrity; 166 (69.2%) were PCR-positive for human β-globin. Of these 166
samples, 31 specimens were not positive for either genotype (18.7%; 95% CI: 13.3–25.0) (Fig
1A). For the remaining 135 samples, HPV 16 genotype was detected in 118 (71.1%; 95% CI:
64.2–77.7) and HPV 18 was detected in 70 (42.2%; 95% CI: 35.1–49.8) (Fig 1A). 31.9% of the
biopsy specimens were positive for both HPV 16 and 18. The primers used in this experiment
were designed to amplify only HPV 16 and 18 subtypes, thus the negative samples were classi-
fied as “untyped” and are presumed to be HPV-positive for non-16 or 18 subtypes, or false
negative by PCR assay.
HPV prevalence in Malian cervical cancer patients
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Prevalence of HPV 16/18 co-infection
In samples where HPV 16 and/or 18 was detected (n = 135), mono-infection with HPV 16 or
HPV 18 was found in 65 (48.2%, 95% CI: 39.9–56.5) and 17 (12.6%; 95% CI: 7.9–19.3) cervical
biopsy samples, respectively (Fig 1B). Co-infection with both HPV 16 and 18 was detected in
53 samples (39.3%; 95% CI: 31.4–47.7).
The age distributions of mono- and co-infected women were different (Fig 1C). Significantly
fewer women aged 30–49 years old were co-infected (N = 18/53; 34.0%; 95% CI: 22.6–47.5) than
women over 50 years old (N = 33/53; 62.3%; 95% CI: 48.8–74.1). No difference was observed for
women under 29 years old, nor was any difference found for the mono-infected women 30–49
years old and over 50 years old (N = 42/82; 51.2%; 95% CI: 40.6–64.7 vs. N = 37/82; 45.1%; 95%
CI: 34.8–55.9). These results may suggest that continued exposure over time, with age, can be a
risk factor for increased co-infection with high-risk HPV 16 and 18 subtypes among older
women diagnosed with CC.
Presence of neutralizing antibodies to HPV 16 and 18
Another means to detect HPV infection (or the efficacy of HPV vaccination) is to measure the
presence of anti-VLP-16 and -18 antibodies in the serum. Blood was obtained from 160 of the
240 patients; serum antibodies were assessed using a cLIA assay to measure the presence of
anti-VLP 16 and 18 antibodies in the serum. HPV 16 antibody-positive blood samples were
Table 2. Characteristics of the 235 women who agreed to participate in the structured interview.
N (235) %
Characteristics
Mean Age (SD) 50.0 (13.2)




Polygamous marriage* 51 22.1
Mean age of first marriage (SD) 17.0 (2.7)
Mean age of sexual debut (SD) 16.0 (2.1)
Average number of children (SD)† 6.0 (2.9)
Mean age when first child born (SD)† 17.0 (2.3)
Ever attended school 40 17.0
Employed outside the home 27 11.5
Medical history
Age of CC diagnosis (SD) 49.0 (13.6)
<29 years 18 7.7
30–49 years 124 52.8
>50 years 92 39.1
Known history of STI 134 57.0
Pruritus, leucorrhea‡ 47 35.1
Other 73 54.5
Notes
* Among those who were married; N = 231.
† Among those with children; N = 229.
‡ Among those with a history of STIs; N = 134
doi:10.1371/journal.pone.0172661.t002
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more frequent (N = 56; 35.0%; 95% CI: 28.0–42.7) than HPV 18 (N = 27; 16.9%; 95% CI: 10.5–
25.9) (Fig 2), which was consistent with the PCR results from this study. However, the propor-
tion of untyped samples was higher using cLIA than PCR (18.5% by PCR vs. 57.5%, 95% CI:
49.8–64.9 by cLIA).
Fig 1. Prevalence of HPV 16 and 18 in women with cervical cancer. A. Percentage of positive samples for
HPV 16 and 18 by PCR (n = 166). Untyped samples were negative for both HPV 16 and 18. B. Percentage of
positive samples for HPV 16 only, HPV 18 only (mono-infection) or both HPV 16 and 18 (co-infection) by PCR
(n = 135). C. Repartition into age groups of positive samples for HPV 16 or HPV 18 (mono-infection) or for both
(co-infection) by PCR. For mono- and co-infections, lighter shades represent the percentage of infected women
within the co- or mono-infected group aged 49 years or younger; darker shades represent the percentage of
infected women aged 50 years or older.
doi:10.1371/journal.pone.0172661.g001
HPV prevalence in Malian cervical cancer patients
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Willingness to participate and autonomy to participate in an HPV vaccine
trial
235 women participated in the oral survey. Two hundred and four participants (86.8%) were
able to recall that they had previously received any vaccine, and 228 (97.0%) said they would like
the HPV vaccine to be available to young adolescent girls in Mali (Table 3). Nearly all partici-
pants (n = 220; 93.6%) also reported that they would be willing to participate in an HPV cancer
vaccine trial (Table 3). Very few of the women reported that they would be able to autonomously
decide to participate in an HPV vaccination study. The majority of women (139 or 59.1%)
reported that a man (father, husband, or both) were identified as decision makers regarding
HPV vaccination consent (Fig 3). Among the 214 (91.1%) women who stated that they would
make the decision themselves, 121 (56.5%) said their husband would also decide. Thus, only 93
women (38.8%) reported that they, alone, could autonomously decide to be vaccinated.
Discussion
This study reveals important information on HPV prevalence and subtype distribution among
women diagnosed with CC in Mali, and to our knowledge, it is the first such study conducted
Fig 2. Detection of HPV16/18 neutralizing antibodies. Presence of antibodies to HPV types 16 and 18 by a VLP-based
competitive Luminex immunoassay (cLIA). Results are presented as percentage of total number of available blood samples
(N = 160).
doi:10.1371/journal.pone.0172661.g002
Table 3. Attitudes about HPV vaccination and decision-making.
N (235) %
Vaccination
Have been vaccinated in the past 204 86.8
Would like the HPV vaccine to be available in Mali to:
Adolescent girls 228 97.0
Adolescent boys 92 39.1
Women 150 63.8
Men 15 6.4
Would participate in a vaccine trial 220 93.6
doi:10.1371/journal.pone.0172661.t003
HPV prevalence in Malian cervical cancer patients
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in Mali since 2002 [17]. This study also provides information to guide the implementation of
HPV vaccines, including therapeutic HPV vaccines in West Africa and the consent process for
engaging women in vaccine trials.
In our study, HPV 16 and/or 18 was detected by PCR for 81.5% of CC patients. This preva-
lence of the infection is consistent with the last study published in 2002 by Bayo et al. [17],
where 96.9% of the 97 women with CC were infected with one of the 8 HPV subtypes tested.
However, the prevalence of HPV subtype 16 was much higher in our study (71.1%) than in the
previous study (50.0%). The same observation was made with HPV 18 (42.2% in our study vs.
12.7% in Bayo et al) and with co-infection (31.9% of the 166 participants in our study vs. only
11.1%). These differences may be due sample size or to differences in the methods used; in the
Bayo et al study, the authors used the PCR enzyme immunoassay method [25] while we per-
formed a PCR using specific primers [21]. Studies in Sub-Saharan African countries have dem-
onstrated that HPV 16 and HPV 18 contribute to 68% of cervical cancers [26]. We found that
HPV 16 and 18 were even more common in this study (confirmed in 82.5% of cervical cancer
patients) however we did not identify the HPV type in 17.5% of subjects. Those subjects may
have had HPV 45, or other types (HPV 35, HPV 33, HPV 52) that have been reported to be
more common in Sub-Saharan Africa [27]. The sample size may not be sufficient to give the
actual distribution of less common HPV subtypes in Mali.
The mortality rate of cervical cancer in Mali is very high (69%). Vaccines that protect
against HPV infection are in use in the developed world, and therapeutic vaccines are in clini-
cal trials [14]. Our results provide support for the introduction of these vaccines in Mali, since
the predominant type of HPV identified in cervical cancer specimens were shown to be one of
the two types that are targeted by the prophylactic vaccines.
Co-infection has been shown to be associated with persistent HPV infection and therefore
has also been associated with development of CC [28]. In a previous meta-analysis, 4–20% of
women with diagnosed CC showed co-infection with HPV 16 and 18 [29]. In our study the
prevalence of co-infection was higher (31.9%). A higher prevalence of co-infection (36%) has
Fig 3. Willingness to participate and who would give permission for participation in a HPV vaccine trial. The percentage of
women willing to participate in a HPV vaccine trial is represented by age group with the line. The bars represent the number of
women answering the question who would give permission to participate to a HPV vaccine trial per age group. The answers were
myself only (dark blue), husband and myself (purple), husband only (pink), father, husband and myself (light blue), parents, husband
and myself (light green), mother only (dark green), or no answer (grey). In the oldest age group, the * asterix indicates data that only
includes 3 patients.
doi:10.1371/journal.pone.0172661.g003
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also been described among women diagnosed with HPV infection in rural Costa Rica [30].
However, our finding could be the result of a possible cross reaction between the HPV16 and
HPV18 primers used in this study, as such cross reaction has been described [31]. The cLIA
assay also showed that 22% of positive samples were positive for both HPV 16 and 18 antibod-
ies (data not shown). This suggests that although co-infection rates measured by PCR in our
study might be overestimated; this group of patient had a higher co-infection rate than previ-
ously described. Co-infection rates were also higher in older study participants. If rate of co-
infection is linked to cervical cancer prevalence, co-infection may be one factor that contrib-
utes to the high prevalence of cervical cancer in West Africa.
As has been reported previously, serology (cLIA assay, in this study) was less sensitive than
the PCR assay to detect type-specific HPV infection in cervical cancer patients. This assay is
primarily used for measuring effective sero-conversion soon after HPV vaccination. Regard-
less, the prevalence of HPV 16 and 18 by these two methods (one or both subtypes found in
81.5% of women by PCR and 43.5% of women by the less-sensitive antibody test) indicate that
these genotypes are associated with CC among Malian women.
HPV prophylactic vaccines were being introduced in Mali at the time of this study and ther-
apeutic HPV cancer vaccines were under development. Thus, we also assessed the willingness
of these women to participate in vaccine trials, and perhaps more important, their ability to
autonomously give consent for participation in a clinical study. Among these participants who
already were affected by cervical cancer, 93.6% were willing to participate in a CC vaccine trial.
In addition, 97% of the participants agreed that the HPV vaccine should be made available to
adolescent girls. This data and similar data published in a companion study [32] provide sup-
port for the introduction of preventive vaccines and suggest that acceptance would be high.
Acceptance of vaccination is critically important to the success of a vaccination campaign [33].
The ability of the female participants in this study to make autonomous decisions reflects
local customs. Most of the participants identified men (husbands and fathers) as the primary
decision-makers regarding their participation in HPV vaccination trials. In our parallel study,
we also assessed autonomy regarding vaccination [32] among community members. The
results were consistent with data collected here. In both studies, men (spouses, heads of house-
hold) were also identified as the primary decision makers about whether their own children
would be able to participate in clinical studies.
Several studies have shown that women’s autonomy is positively related to children’s health
outcomes [34]. Since the rate of cervical cancer is so high, and cancer screening is not univer-
sally available in Mali [35], it is clear that an important strategy for the successful introduction
of HPV vaccination would be to engage both men and women in education about the link
between HPV and cervical cancer and the efficacy of HPV vaccination. Additional research is
needed to further clarify the decision-making dynamics with regard to HPV vaccination of
dependent children and to incorporate this information into public awareness messages and
targeted HPV vaccine campaigns.
We also note that the women in this study reported that their age of sexual debut was 16,
consistent with published studies for this region of the world [17]. Prophylactic HPV vaccina-
tion has been approved for children prior to their sexual debut, and the maximum age for vac-
cination is therefore set at 12 to 13 in many parts of the world. This study supports the concept
that HPV vaccination could be extended to girls up to the age of 15 in Mali.
Even though cervical cancer screening is available in certain health clinics in Bamako, lack
of public awareness about HPV and CC is one of the most important barriers to effective CC
prevention. Additional studies by our group [32] have demonstrated that limited knowledge
about the purpose and location of CC screens is a problem that must be addressed in order to
achieve greater HPV and CC prevention.
HPV prevalence in Malian cervical cancer patients
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In conclusion, this study provides important information on HPV prevalence and subtype
distribution among women diagnosed with CC in Mali, and to our knowledge, it is the first
such study conducted in Mali since 2002 [17]. Our study supports the implementation of
prophylactic HPV vaccination programs with vaccines against subtypes 16 and 18 in Mali in
concordance with WHO recommendations [36] and provides information to guide future
interventions for executing successful vaccination campaigns in West Africa. Our study shows
that HPV vaccination is desired, and also confirms the need to engage male partners or heads
of households in the decision-making process, regarding HPV vaccination. Urgent implemen-
tation of HPV vaccination in Mali will avert tens of thousands of deaths and is critically impor-
tant for the wellbeing of Malian women and their families.
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